Novocure (NSDQ:NVCR) said today that the 1st patient was enrolled in a Phase II pilot trial evaluating Optune with bevacizumab, a chemotherapy, for patients with refractory recurrent glioblastoma. In recurrent GBM, Optune and bevacizumab are approved as monotherapies. Novocure’s consortium study is slated to evaluate the efficacy and safety of the Optune-chemo combo in patients […]
Featured
Surefire Medical touts infusion tech in liver cancer trial
Surefire Medical touted data today from a retrospective analysis of 85 bridge-to-transplant liver cancer patients treated with transarterial chemoembolization. The data showed that therapy delivered using the Surefire infusion system yielded an 80% complete response in 1 treatment compared to 52% with a standard endhole microcatheter. The analysis also demonstrated a lower recurrence rate of […]
Kentucky doc gets jail time for bad opioid prescription habits & Medicaid fraud
Dr. George Kudmani, an OB/GYN from Kentucky, was sentenced to 4 years in prison this week after a federal jury ruled that he was guilty of inappropriately doling out opioids and Medcaid fraud. The jury found Kudmani guilty of 19 counts of unlawful distribution of controlled substances and 8 counts of health care fraud. After Kudmani serves his […]
ivWatch raises $14.8m for infusion therapy tech
ivWatch said today that it closed a $14.8 million financing round to support the company’s direct go-to-market initiatives and strategic partners activities. Undisclosed angel investors, family funds and a major hospital system invested in the round, according to the company. “The support ivWatch has seen from our investors and partners has been incredible. They are […]
Amaranth Medical looks to recapture the potential of bioresorbable scaffolds
Dr. Antonio Colombo had finished his presentation of 9-month data for Amaranth Medical‘s Aptitude sirolimus-eluting bioresorbable scaffold when an audience member asked about adverse events. He told the EuroPCR attendee that they hadn’t seen any adverse events related to the device during the trial – and that’s unusual. Bioresorbable scaffolds, like Abbott‘s (NYSE:ABT) Absorb, have been […]
Novavax touts nanoparticle RSV vaccine in women of child-bearing age
Novavax Inc. (NSDQ:NVAX) touted data today from the second Phase II trial of its RSV F nanoparticle vaccine candidate in women of child-bearing age. The research was published in the journal Vaccine. Novavax’s nanomedicine vaccine is being developed to protect infants from the respiratory syncytial virus. The Gaithersburg, Md.-based company presented top-line data from the Phase […]
Diabetes double play: Medtronic launches MiniMed 670G, Dexcom wins FDA nod for Android G5 app
Medtronic (NYSE:MDT) and Dexcom (NSDQ:DXCM) today announced respective wins for their diabetes care tech, with Medtronic launching its hybrid closed loop MiniMed 670G in the US and Dexcom winning an FDA nod for a Google (NSDQ:GOOG) Android G5 Mobile application. Fridley, Minn.-based Medtronic’s MiniMed 670G is designed to automatically track and adjust blood sugar levels in patients […]
Glytec highlights hospital cost-savings for insulin therapy
At the 6th International Hospital Diabetes meeting, Glytec‘s eGlycemic Management System was featured in several studies demonstrating the products’s ability to save hospitals money. One case study presented at the meeting described a health system that adopted Glytec’s eGlycemic Management System and saw 1st-year cost savings of $7.5 million. The Kaweah Delta Medical Center attributed the […]
Magellan widens lead test recall
The FDA this week expanded its Class I recall of lead poisoning tests from Magellan Diagnostics to include 2 additional testing systems. The regulatory watchdog said it recalled Magellan’s LeadCare testing systems because they may underestimate blood lead levels and provide inaccurate results with venous blood samples. “Falsely lower test results may lead to improper patient […]
Mallinckrodt launches pivotal trial for StrataGraft regenerative skin graft
Mallinckrodt (NYSE:MNK) said today that it enrolled the 1st patient in the pivotal Phase III trial of its StrataGraft skin tissue graft. The study is slated to include patients with 3% to 49% total body surface area of severe thermal burns. Researchers intend to evaluate outcomes including the area of StrataGraft treatment site that requires a subsequent […]